Publication Date:
2012-07-11
Description:
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network British Journal of Cancer 107, 280 (10 July 2012). doi:10.1038/bjc.2012.257 Authors: K Mross, C Dittrich, W E Aulitzky, D Strumberg, J Schutte, R M Schmid, S Hollerbach, M Merger, G Munzert, F Fleischer & M E Scheulen
Keywords:
pancreatic cancerPlk1 inhibitorphase IIBI 2536
Print ISSN:
0007-0920
Electronic ISSN:
1532-1827
Topics:
Medicine
Permalink